Supreme Court Review Of Biosimilars Law Closer?
This article was originally published in Scrip
Executive Summary
Novartis AG unit Sandoz Inc. is mulling over whether to seek an appeal to the US Supreme Court of an appeals court ruling in a case involving the firm's biosimilar Zarxio (filgrastim-sndz) – a lawsuit brought by Amgen Inc.